# ThirtyFiveBio

**Canonical:** https://apis.io/providers/thirtyfivebio/  
**Website:** https://www.thirtyfivebio.com/  
**APIs profiled:** 0

ThirtyFiveBio is an Oxford, UK biotechnology company founded in 2021 to develop first-in-class small-molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal diseases, including ulcerative colitis, inflammatory bowel disease, and digestive-tract cancers. The company was incubated by the M:M Bio (Molecule to Medicine) drug-discovery ecosystem together with Canaan Partners, and is backed by AbbVie Ventures, Mayewell Capital, and Innovate UK. It is a preclinical drug-discovery company with plans for first-in-human trials, not a software or API provider; this profile carries no developer API surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Pharmaceuticals, Drug Discovery, Gastrointestinal, Life Sciences, Healthcare, Therapeutics

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/thirtyfivebio/). Scores are computed from the provider's own public artifacts under a published rubric.